Bionano Genomics’ Revenue by Region (2018 – 2022)

You need Pro Plan to access KPI data.

Get 60% off on Pro

Discount ends in:

00
Days
00
Hours
00
Mins.
00
Seconds

.

Exclusive Data

You need the Pro Plan for unlimited access.

Pro Plan

$49 per month*

60% discount ends in:

00
Days
00
Hours
00
Mins.
00
Seconds

About

This statistic highlights Bionano Genomics’ Revenue by Region, split between the Asia Pacific, EMEIA, and North America, reported on a quarterly basis from Q1 2018 onwards.
Subscribe to Pro or Enterprise plans to unlock this feature.
More information

Subscribe to Pro or Enterprise plans to unlock this feature.

Contact the Analyst

Subscribe to Pro or Enterprise plans to unlock this feature.

Become a smarter investor today.

Access Business Quant for as low as $19/month

Become a smarter investor today.

Access KPIs & Segment Financials on US stocks

This statistic highlights Bionano Genomics’ Revenue by Region, split between the Asia Pacific, EMEIA, and North America, reported on a quarterly basis from Q1 2018 onwards.

Bionano Genomics is a global pioneer in optical genome mapping technologies for genome analysis. where the company examines the structural variations of long segments of genomic DNA and other biomolecules The company provides proprietary nanochannel chips, an automated imaging instrument, integrated primary and secondary software, and application-specific reagents. Based on the Saphyr system, the company provides tools and services to scientists and clinicians conducting genetic research and patient testing. Through its owned subsidiary, Lineagen, Inc., the firm also provides diagnostic testing services for child patients suspected of having neurodevelopmental impairments.

Bionano Genomics’ Revenue by Region

Bionano Genomics’ generates its revenue from the following regions:

  • Asia Pacific
  • Europe, Middle East, India, and Africa (EMEIA)
  • North America

The following table sheds more light on each of the region and their contribution to the company’s overall top line.

Regions Q1 2020 Q1 2021 YOY Growth Revenue Share in Q1 2021
Asia Pacific $20.00 $83.00 315.00% 2.62%
EMEIA $390.00 $1,587.00 306.92% 50.09%
North America $726.00 $1,498.00 106.34% 47.29%
Total $1,136.00 $3,168.00 178.87% 100.00%

(All figures in thousands, except percentages)

Bionano Genomics’ Inc’s total revenue has been steadily increasing from $1,136 thousand in Q1 2020 to $3,168 thousand in Q1 2021, which shows a 178.87% increase year-over-year.

Bionano Genomics’ Inc revenue is further bifurcated into the following regions:

Asia Pacific

China, Japan, South Korea, Singapore, and Australia are all part of the Asia Pacific region.

This region contributed 2.62% of the total revenue in Q1 2021. Its revenue grew from $20 thousand in Q1 2020 to $83 thousand in Q1 2021, which shows a 315% increase. In 2020, this region’s revenue steadily increased from $20 thousand in Q1 2020 to $630thousand in Q1 2021.

EMEIA

EMEIA region includes Europe, Middle East, India, and Africa.

A majority of Bionano Genomics’ revenue comes from EMEIA, which contributed about 50.09% of total revenue in Q1 2021 amounting to $1,587 thousand. There was a 306.92% increase in revenue compared to the previous year where the revenue generated from this region was $390 thousand.

North America

In the North America region, the company operates in the United States and Canada.

This region contributed 47.29% of the total revenue in Q1 2021. Its revenue grew from $726 thousand in Q1 2020 to $1,498 thousand in Q1 2021, which is a 106.34% increase.

For the fiscal years ended December 31, 2020, and 2019, the United States accounted for 42 % and 47 % revenue, respectively, while China accounted for 8 % and 7%.

Company Overview

Han Cao founded the Bionano Genomics’ in January 2003, and it is headquartered in San Diego, California, United States. Bionano Genomics’ traded on the NASDAQ under the symbol “BNGO”. In its initial public offering on September 21, 2018, its stock opened at $6.13. The company faces tough competition from Nabsys, PacBio, Genomic Vision, GenapSys, Oxford Nanopore, GnuBIO, LaserGen, OncoDNA, and QIAGEN.

Bionano Genomics’ had 147 employees as of December 31, 2020, with 72 workings in sales, sales support, and marketing, 38 in research and development, 24 in operations, and 13 in general and administrative. 126 of the 147 employees were based in the United States, with the remaining 21 working in countries other than the United States. Lineagen, Inc. has been acquired by the company to accelerate the clinical adoption of Saphyr for Digital Cytogenetics.

Did you like Bionano Genomics’ Revenue by Region statistic?

Access thousands of more such key performance indicator data points, on listed companies, with Business Quant.

You can also get started for free.

Read more

Our Plans

Always know what you’ll pay. No hidden costs or surprises.

  • Annual
  • Monthly

Basic

$0
per month

Get to know us

  • Access basic data
  • No credit card required
Start for Free

60% discount until September 30

Pro

$19
per month*

For serious investing

  • Granular KPI data
  • Stock research tools
  • Industry data & tools
Buy Now

Enterprise

$99
per month, onwards*

For tailored workflows

  • All of Pro plan
  • Custom built features
Contact Us

* Billed annually, local taxes extra. 

Basic

$0
per month

Get to know us

  • Access basic data
  • No credit card required
Start for Free

60% discount on Annual plan

Pro

$49
per month*

For serious investing

  • Granular KPI data
  • Stock research tools
  • Industry data & tools
Buy Now

Enterprise

$99
per month, onwards*

For tailored workflows

  • All of Pro plan
  • Custom built features
Contact Us

* Local taxes extra. 

BQ Star Yellow 60%

Get Pro for 60% off

  • Access all features immediately
  • Datasets updated every day
  • Export data in CSV and XLSX formats

Offer Ends In

Starting from $49 $19 / month

.